Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy Participants

NCT07072611 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Cutaneous Lupus Erythematosus

Interventions

DRUG: SOF-SKN 0.25%
DRUG: SOF-SKN 0.5%
DRUG: SOF-SKN 1%
DRUG: SOF-SKN 2%
DRUG: Placebo

Sponsor

Noxopharm Limited